---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-290972"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-12-08T23:59:59+00:00"
generated_at: "2026-06-07T15:37:26.705075+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave Life Sciences prices $100M public offering of 20M shares at $5.00; pipeline updates also disclosed

## Summary
- Underwritten public offering of 20M ordinary shares at $5.00/share, gross proceeds ~$100M; 30-day option for additional 3M shares.
- Offering expected to close Dec 11, 2023; J.P. Morgan and Leerink Partners are joint book-runners.
- Cash runway (including offering net proceeds and $20M GSK milestone) expected to fund operations into Q4 2025.
- Initiated dosing in RestorAATion trial for WVE-006 (AATD); earned $20M GSK milestone; proof-of-mechanism data expected 2024.
- INHBE clinical candidate for metabolic disorders including obesity expected Q4 2024 selection, CTA in 2025.

## SEC filing metadata
- accession: 0001193125-23-290972
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-12-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523290972/0001193125-23-290972-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523290972/d60594d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-290972
- JSON: https://secwatch.observer/filing/0001193125-23-290972.json
- Plain text: https://secwatch.observer/filing/0001193125-23-290972.txt

## Key facts
- Material Agreements
  Wave Life Sciences Ltd. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $5.00 per Share (effective 2023-12-06).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters
  - Value: $5.00 per Share
  - Effective: 2023-12-06
  source text: On December 6, 2023, Wave Life Sciences Ltd. (the “Company”, “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC and Leerink Partners LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale in an underwritten offering (the “Offering”) by the Company of an aggregate of 20,000,000 of the Company’s ordinary shares, no par value (the “Firm Shares”), at a public offering price of $5.00 per Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523290972/0001193125-23-290972-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.